Johns Hopkins HIV Guide
Emtricitabine
INDICATIONS
FDA
FDA
- Treatment of HIV infection in combination with other antiretroviral agents (2003).
- Pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate or tenofovir alafenamide
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Treatment of hepatitis B in HIV-HBV co-infected patients
- Post-exposure prophylaxis (PEP) in combination with other agents
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: January 23, 2023
Citation
Auwaerter, Paul G, and Janessa Smith. "Emtricitabine." Johns Hopkins HIV Guide, The Johns Hopkins University, 2023. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545063/all/Emtricitabine.
Auwaerter PG, Smith J. Emtricitabine. Johns Hopkins HIV Guide. The Johns Hopkins University; 2023. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545063/all/Emtricitabine. Accessed November 4, 2025.
Auwaerter, P. G., & Smith, J. (2023). Emtricitabine. In Johns Hopkins HIV Guide. The Johns Hopkins University. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545063/all/Emtricitabine
Auwaerter PG, Smith J. Emtricitabine [Internet]. In: Johns Hopkins HIV Guide. The Johns Hopkins University; 2023. [cited 2025 November 04]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545063/all/Emtricitabine.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Emtricitabine
ID - 545063
A1 - Auwaerter,Paul,M.D.
AU - Smith,Janessa,Smith
Y1 - 2023/01/23/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545063/all/Emtricitabine
PB - The Johns Hopkins University
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
